Tim Lahm
Concepts (476)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 58 | 2026 | 1957 | 9.230 |
Why?
| | Ventricular Dysfunction, Right | 23 | 2026 | 248 | 6.690 |
Why?
| | Ventricular Function, Right | 20 | 2026 | 297 | 4.540 |
Why?
| | Pulmonary Artery | 26 | 2026 | 1129 | 3.340 |
Why?
| | Hypoxia | 19 | 2025 | 1199 | 2.460 |
Why?
| | Estradiol | 9 | 2026 | 515 | 2.290 |
Why?
| | Estrogen Receptor alpha | 6 | 2024 | 151 | 2.260 |
Why?
| | Estrogens | 11 | 2023 | 367 | 1.840 |
Why?
| | Endothelial Cells | 11 | 2025 | 877 | 1.630 |
Why?
| | Hypertrophy, Right Ventricular | 9 | 2023 | 149 | 1.520 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 3 | 2021 | 51 | 1.380 |
Why?
| | Pulmonary Embolism | 4 | 2023 | 241 | 1.340 |
Why?
| | Gonadal Steroid Hormones | 8 | 2026 | 143 | 1.250 |
Why?
| | Estrogen Receptor beta | 3 | 2018 | 40 | 1.250 |
Why?
| | Rats, Sprague-Dawley | 30 | 2025 | 2525 | 1.240 |
Why?
| | Heart Failure | 9 | 2026 | 2326 | 1.230 |
Why?
| | Familial Primary Pulmonary Hypertension | 10 | 2023 | 196 | 1.230 |
Why?
| | Vasoconstriction | 8 | 2008 | 216 | 1.210 |
Why?
| | Sex Characteristics | 10 | 2022 | 789 | 1.130 |
Why?
| | Ventricular Remodeling | 7 | 2026 | 278 | 1.080 |
Why?
| | Receptors, Estrogen | 4 | 2023 | 404 | 1.070 |
Why?
| | Nitric Oxide | 5 | 2021 | 892 | 1.050 |
Why?
| | Lung | 13 | 2025 | 4116 | 1.040 |
Why?
| | Animals | 70 | 2026 | 38097 | 1.010 |
Why?
| | Rats | 29 | 2025 | 5585 | 0.980 |
Why?
| | Ventricular Function, Left | 5 | 2019 | 544 | 0.970 |
Why?
| | Adaptation, Physiological | 4 | 2024 | 560 | 0.940 |
Why?
| | Lung Diseases | 5 | 2025 | 782 | 0.920 |
Why?
| | Apelin | 3 | 2021 | 10 | 0.920 |
Why?
| | Heart | 5 | 2020 | 626 | 0.860 |
Why?
| | Male | 65 | 2026 | 73003 | 0.760 |
Why?
| | Disease Models, Animal | 20 | 2025 | 4568 | 0.760 |
Why?
| | Humans | 88 | 2026 | 145763 | 0.750 |
Why?
| | Health Status Disparities | 1 | 2026 | 321 | 0.740 |
Why?
| | Sex Factors | 12 | 2026 | 2110 | 0.720 |
Why?
| | Heart Ventricles | 9 | 2024 | 756 | 0.720 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2018 | 298 | 0.670 |
Why?
| | Vascular Endothelial Growth Factor A | 11 | 2024 | 552 | 0.650 |
Why?
| | Veterans | 6 | 2020 | 1642 | 0.640 |
Why?
| | Ventricular Pressure | 7 | 2022 | 52 | 0.630 |
Why?
| | Stenosis, Pulmonary Artery | 1 | 2020 | 4 | 0.620 |
Why?
| | Renin-Angiotensin System | 1 | 2020 | 80 | 0.620 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2020 | 115 | 0.610 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2020 | 69 | 0.610 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 229 | 0.590 |
Why?
| | Iron | 2 | 2021 | 359 | 0.580 |
Why?
| | Cardiovascular System | 1 | 2020 | 139 | 0.570 |
Why?
| | Vascular Remodeling | 6 | 2025 | 209 | 0.560 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2020 | 67 | 0.560 |
Why?
| | Telangiectasia, Hereditary Hemorrhagic | 1 | 2018 | 14 | 0.560 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2018 | 23 | 0.550 |
Why?
| | Histamine H2 Antagonists | 1 | 2018 | 23 | 0.550 |
Why?
| | Lung Injury | 2 | 2015 | 249 | 0.550 |
Why?
| | Neovascularization, Pathologic | 2 | 2017 | 287 | 0.540 |
Why?
| | Bronchodilator Agents | 2 | 2017 | 187 | 0.540 |
Why?
| | Liver Diseases | 1 | 2021 | 305 | 0.520 |
Why?
| | Female | 48 | 2026 | 79035 | 0.510 |
Why?
| | Vascular Diseases | 1 | 2020 | 252 | 0.510 |
Why?
| | Up-Regulation | 4 | 2021 | 848 | 0.510 |
Why?
| | Oxygen Inhalation Therapy | 2 | 2017 | 181 | 0.500 |
Why?
| | Myocardial Contraction | 3 | 2017 | 293 | 0.500 |
Why?
| | Hyperoxia | 2 | 2015 | 107 | 0.500 |
Why?
| | Intention | 1 | 2018 | 186 | 0.480 |
Why?
| | High-Intensity Interval Training | 1 | 2016 | 45 | 0.470 |
Why?
| | Research | 1 | 2018 | 431 | 0.440 |
Why?
| | Cell Hypoxia | 7 | 2018 | 247 | 0.440 |
Why?
| | Reperfusion Injury | 4 | 2011 | 292 | 0.430 |
Why?
| | Physical Conditioning, Animal | 3 | 2025 | 242 | 0.390 |
Why?
| | Hemodynamics | 7 | 2022 | 1118 | 0.390 |
Why?
| | Blood Pressure | 4 | 2015 | 1782 | 0.380 |
Why?
| | Hypertension | 2 | 2021 | 1276 | 0.360 |
Why?
| | Signal Transduction | 10 | 2025 | 5223 | 0.350 |
Why?
| | Whipple Disease | 1 | 2011 | 7 | 0.350 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2012 | 63 | 0.350 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 20 | 0.340 |
Why?
| | Embolism, Air | 1 | 2011 | 14 | 0.340 |
Why?
| | Magnesium Sulfate | 1 | 2011 | 18 | 0.340 |
Why?
| | Pneumothorax | 1 | 2011 | 52 | 0.330 |
Why?
| | HIV Infections | 1 | 2026 | 3195 | 0.330 |
Why?
| | Pulmonary Medicine | 2 | 2024 | 78 | 0.330 |
Why?
| | Leukapheresis | 1 | 2010 | 27 | 0.320 |
Why?
| | Calcium Channel Blockers | 1 | 2011 | 166 | 0.320 |
Why?
| | Bradykinin | 1 | 2010 | 49 | 0.310 |
Why?
| | Pulmonary Circulation | 3 | 2023 | 430 | 0.310 |
Why?
| | Paracrine Communication | 6 | 2008 | 67 | 0.300 |
Why?
| | Sepsis | 3 | 2010 | 664 | 0.290 |
Why?
| | Leukocytes | 1 | 2010 | 296 | 0.290 |
Why?
| | Myocardium | 5 | 2020 | 935 | 0.280 |
Why?
| | Calcium | 2 | 2012 | 1191 | 0.280 |
Why?
| | Blastomycosis | 1 | 2008 | 11 | 0.280 |
Why?
| | Altitude | 2 | 2024 | 463 | 0.270 |
Why?
| | Aged | 14 | 2021 | 26215 | 0.270 |
Why?
| | Acute Lung Injury | 1 | 2011 | 307 | 0.260 |
Why?
| | Lab-On-A-Chip Devices | 2 | 2025 | 61 | 0.260 |
Why?
| | Fellowships and Scholarships | 2 | 2024 | 354 | 0.260 |
Why?
| | Biomedical Research | 2 | 2025 | 719 | 0.260 |
Why?
| | Endothelins | 1 | 2007 | 61 | 0.250 |
Why?
| | Stroke Volume | 3 | 2020 | 655 | 0.250 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2007 | 76 | 0.250 |
Why?
| | Cardiotonic Agents | 2 | 2021 | 94 | 0.250 |
Why?
| | Administration, Inhalation | 2 | 2019 | 571 | 0.240 |
Why?
| | Vascular Resistance | 2 | 2020 | 370 | 0.240 |
Why?
| | Menstrual Cycle | 1 | 2007 | 145 | 0.240 |
Why?
| | Middle Aged | 15 | 2021 | 36302 | 0.230 |
Why?
| | Image Cytometry | 1 | 2025 | 11 | 0.230 |
Why?
| | Monocrotaline | 3 | 2022 | 31 | 0.230 |
Why?
| | Adult | 15 | 2024 | 40872 | 0.230 |
Why?
| | Adenosine Deaminase | 1 | 2025 | 43 | 0.220 |
Why?
| | Fruit and Vegetable Juices | 1 | 2025 | 22 | 0.220 |
Why?
| | Calcium Signaling | 1 | 2007 | 245 | 0.220 |
Why?
| | Survival Analysis | 2 | 2026 | 1378 | 0.220 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2025 | 79 | 0.220 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 484 | 0.220 |
Why?
| | Nitrates | 1 | 2025 | 96 | 0.210 |
Why?
| | Rats, Mutant Strains | 2 | 2021 | 19 | 0.210 |
Why?
| | Neoplasms | 1 | 2020 | 2913 | 0.210 |
Why?
| | Propionates | 2 | 2018 | 39 | 0.210 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2007 | 457 | 0.200 |
Why?
| | Myocardial Reperfusion Injury | 3 | 2010 | 139 | 0.200 |
Why?
| | United States | 13 | 2025 | 16123 | 0.200 |
Why?
| | Microtubules | 1 | 2026 | 265 | 0.200 |
Why?
| | Mice | 15 | 2026 | 18355 | 0.200 |
Why?
| | Antihypertensive Agents | 2 | 2018 | 521 | 0.200 |
Why?
| | Autophagy | 2 | 2016 | 291 | 0.200 |
Why?
| | Reproductive Health Services | 1 | 2023 | 19 | 0.200 |
Why?
| | Databases, Factual | 2 | 2020 | 1491 | 0.190 |
Why?
| | SOXF Transcription Factors | 2 | 2023 | 16 | 0.190 |
Why?
| | Nitriles | 2 | 2018 | 211 | 0.190 |
Why?
| | Chloride Channels | 1 | 2023 | 33 | 0.190 |
Why?
| | Double-Blind Method | 2 | 2019 | 2064 | 0.190 |
Why?
| | Myocytes, Cardiac | 3 | 2021 | 546 | 0.190 |
Why?
| | Stem Cell Transplantation | 3 | 2008 | 189 | 0.190 |
Why?
| | Echocardiography | 2 | 2017 | 648 | 0.190 |
Why?
| | United States Department of Veterans Affairs | 2 | 2017 | 779 | 0.180 |
Why?
| | Chlorides | 1 | 2023 | 138 | 0.180 |
Why?
| | Aged, 80 and over | 7 | 2021 | 8346 | 0.180 |
Why?
| | RNA-Binding Proteins | 1 | 2025 | 447 | 0.170 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2667 | 0.170 |
Why?
| | Intercellular Signaling Peptides and Proteins | 3 | 2015 | 376 | 0.170 |
Why?
| | Dehydroepiandrosterone Sulfate | 1 | 2021 | 43 | 0.170 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 361 | 0.170 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2022 | 166 | 0.170 |
Why?
| | Menopause, Premature | 1 | 2021 | 12 | 0.170 |
Why?
| | Societies, Medical | 3 | 2025 | 900 | 0.170 |
Why?
| | Atrial Pressure | 1 | 2020 | 3 | 0.160 |
Why?
| | Cells, Cultured | 7 | 2025 | 4151 | 0.160 |
Why?
| | Cytokines | 5 | 2015 | 2069 | 0.160 |
Why?
| | Metabolic Diseases | 1 | 2021 | 114 | 0.160 |
Why?
| | Phenylephrine | 3 | 2008 | 74 | 0.160 |
Why?
| | Vasodilator Agents | 2 | 2013 | 330 | 0.160 |
Why?
| | Hormones | 1 | 2021 | 135 | 0.160 |
Why?
| | Receptors, Androgen | 1 | 2021 | 149 | 0.160 |
Why?
| | Body Weight | 2 | 2015 | 972 | 0.160 |
Why?
| | Testosterone | 4 | 2014 | 416 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1582 | 0.150 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 4 | 2022 | 103 | 0.150 |
Why?
| | Models, Cardiovascular | 1 | 2021 | 196 | 0.150 |
Why?
| | Drugs, Investigational | 1 | 2019 | 31 | 0.150 |
Why?
| | Ovariectomy | 4 | 2015 | 166 | 0.150 |
Why?
| | Education, Medical, Graduate | 1 | 2024 | 562 | 0.150 |
Why?
| | Inflammation | 3 | 2024 | 2883 | 0.150 |
Why?
| | Organ Size | 1 | 2020 | 461 | 0.150 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 231 | 0.150 |
Why?
| | Vasoconstrictor Agents | 3 | 2008 | 150 | 0.150 |
Why?
| | Young Adult | 8 | 2021 | 14251 | 0.150 |
Why?
| | Mice, Knockout | 4 | 2021 | 3130 | 0.150 |
Why?
| | Mesenchymal Stem Cell Transplantation | 3 | 2008 | 59 | 0.150 |
Why?
| | Cardiac Catheterization | 2 | 2020 | 559 | 0.140 |
Why?
| | HLA-DP alpha-Chains | 1 | 2018 | 4 | 0.140 |
Why?
| | Muscle, Skeletal | 3 | 2025 | 1791 | 0.140 |
Why?
| | Y Chromosome | 1 | 2018 | 37 | 0.140 |
Why?
| | Gender Identity | 1 | 2019 | 129 | 0.140 |
Why?
| | RNA, Long Noncoding | 1 | 2021 | 172 | 0.140 |
Why?
| | Lipopolysaccharides | 4 | 2010 | 858 | 0.140 |
Why?
| | Troponin T | 1 | 2019 | 63 | 0.140 |
Why?
| | Respiratory Mucosa | 1 | 2021 | 322 | 0.140 |
Why?
| | Animals, Newborn | 4 | 2015 | 896 | 0.140 |
Why?
| | Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2018 | 21 | 0.140 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2016 | 203 | 0.140 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2018 | 27 | 0.140 |
Why?
| | Risk Factors | 3 | 2026 | 10917 | 0.140 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 23 | 0.140 |
Why?
| | Propensity Score | 1 | 2020 | 377 | 0.140 |
Why?
| | Arterial Pressure | 2 | 2016 | 134 | 0.140 |
Why?
| | Adult Stem Cells | 2 | 2008 | 40 | 0.140 |
Why?
| | HLA-DP beta-Chains | 1 | 2018 | 88 | 0.140 |
Why?
| | Oxygen Consumption | 2 | 2024 | 719 | 0.140 |
Why?
| | RNA, Messenger | 4 | 2021 | 2805 | 0.140 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2017 | 264 | 0.140 |
Why?
| | Metabolome | 1 | 2021 | 391 | 0.130 |
Why?
| | Isolated Heart Preparation | 1 | 2017 | 6 | 0.130 |
Why?
| | Apoptosis | 3 | 2025 | 2443 | 0.130 |
Why?
| | Bronchoscopy | 3 | 2021 | 227 | 0.130 |
Why?
| | Protein Stability | 1 | 2018 | 176 | 0.130 |
Why?
| | bcl-2-Associated X Protein | 1 | 2017 | 53 | 0.130 |
Why?
| | Cardiac Output | 3 | 2015 | 179 | 0.130 |
Why?
| | Risk Assessment | 4 | 2023 | 3752 | 0.130 |
Why?
| | Peptide Fragments | 2 | 2019 | 696 | 0.130 |
Why?
| | Diastole | 1 | 2017 | 146 | 0.130 |
Why?
| | CD55 Antigens | 1 | 2016 | 29 | 0.120 |
Why?
| | Dietary Supplements | 1 | 2021 | 584 | 0.120 |
Why?
| | Myocardial Infarction | 2 | 2019 | 1211 | 0.120 |
Why?
| | Pyrroles | 1 | 2017 | 220 | 0.120 |
Why?
| | Computed Tomography Angiography | 1 | 2017 | 146 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 241 | 0.120 |
Why?
| | Women's Health | 1 | 2018 | 316 | 0.120 |
Why?
| | Metabolic Syndrome | 1 | 2020 | 361 | 0.120 |
Why?
| | Epithelium | 1 | 2016 | 311 | 0.110 |
Why?
| | Dyspnea | 1 | 2017 | 250 | 0.110 |
Why?
| | Personnel Selection | 1 | 2017 | 91 | 0.110 |
Why?
| | Research Report | 1 | 2016 | 86 | 0.110 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2019 | 394 | 0.110 |
Why?
| | Golgi Apparatus | 1 | 2015 | 99 | 0.110 |
Why?
| | Melanocytes | 1 | 2015 | 65 | 0.110 |
Why?
| | Biological Assay | 1 | 2016 | 132 | 0.110 |
Why?
| | Genetic Testing | 1 | 2018 | 483 | 0.110 |
Why?
| | Telemetry | 1 | 2015 | 40 | 0.110 |
Why?
| | Physical Exertion | 1 | 2016 | 205 | 0.110 |
Why?
| | Stem Cells | 3 | 2008 | 630 | 0.110 |
Why?
| | Mice, Inbred C57BL | 9 | 2025 | 5992 | 0.110 |
Why?
| | Physical Endurance | 1 | 2016 | 279 | 0.110 |
Why?
| | Pulmonary Blastoma | 1 | 2014 | 8 | 0.110 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2015 | 69 | 0.110 |
Why?
| | Health Services Accessibility | 1 | 2023 | 1101 | 0.110 |
Why?
| | Macrophages | 1 | 2022 | 1507 | 0.110 |
Why?
| | Models, Biological | 6 | 2021 | 1764 | 0.100 |
Why?
| | Sleep Wake Disorders | 1 | 2018 | 314 | 0.100 |
Why?
| | Familial Hypophosphatemic Rickets | 1 | 2014 | 6 | 0.100 |
Why?
| | Health Policy | 1 | 2017 | 400 | 0.100 |
Why?
| | Dehydroepiandrosterone | 1 | 2014 | 49 | 0.100 |
Why?
| | Chest Pain | 1 | 2014 | 99 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1270 | 0.100 |
Why?
| | Transcriptome | 1 | 2020 | 1042 | 0.100 |
Why?
| | Indoles | 1 | 2017 | 507 | 0.100 |
Why?
| | Splenectomy | 1 | 2013 | 61 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2016 | 11793 | 0.100 |
Why?
| | World Health Organization | 1 | 2013 | 104 | 0.100 |
Why?
| | Ovary | 1 | 2015 | 234 | 0.100 |
Why?
| | Phosphates | 1 | 2014 | 177 | 0.090 |
Why?
| | Pulmonary Alveoli | 1 | 2015 | 387 | 0.090 |
Why?
| | Fever | 1 | 2014 | 319 | 0.090 |
Why?
| | Precision Medicine | 1 | 2017 | 461 | 0.090 |
Why?
| | Diagnosis, Differential | 2 | 2014 | 1512 | 0.090 |
Why?
| | Pulmonary Veins | 1 | 2014 | 108 | 0.090 |
Why?
| | Oxygen | 2 | 2015 | 981 | 0.090 |
Why?
| | Ischemia | 3 | 2015 | 422 | 0.090 |
Why?
| | Fibroblast Growth Factors | 1 | 2014 | 188 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2011 | 2028 | 0.090 |
Why?
| | Myocardial Ischemia | 3 | 2008 | 285 | 0.090 |
Why?
| | Asthma | 2 | 2021 | 1797 | 0.090 |
Why?
| | Estrogen Antagonists | 1 | 2012 | 37 | 0.090 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 64 | 0.090 |
Why?
| | Mutation, Missense | 1 | 2014 | 335 | 0.090 |
Why?
| | ROC Curve | 1 | 2014 | 618 | 0.090 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2015 | 339 | 0.090 |
Why?
| | Exercise | 1 | 2024 | 2205 | 0.090 |
Why?
| | Airway Remodeling | 1 | 2012 | 63 | 0.090 |
Why?
| | Myocardial Perfusion Imaging | 1 | 2011 | 50 | 0.090 |
Why?
| | Length of Stay | 1 | 2017 | 1350 | 0.090 |
Why?
| | Models, Animal | 2 | 2010 | 392 | 0.090 |
Why?
| | Heart Arrest | 1 | 2015 | 411 | 0.080 |
Why?
| | Oxidoreductases | 1 | 2011 | 91 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2008 | 1217 | 0.080 |
Why?
| | Ceramides | 1 | 2011 | 117 | 0.080 |
Why?
| | Endothelium, Vascular | 2 | 2007 | 956 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 736 | 0.080 |
Why?
| | Exercise Test | 2 | 2024 | 630 | 0.080 |
Why?
| | Exercise Therapy | 1 | 2015 | 475 | 0.080 |
Why?
| | Acute Disease | 2 | 2010 | 1036 | 0.080 |
Why?
| | Retrospective Studies | 4 | 2017 | 17325 | 0.080 |
Why?
| | Immunomodulation | 1 | 2010 | 99 | 0.080 |
Why?
| | Angiopoietin-1 | 1 | 2009 | 12 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2191 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2015 | 1450 | 0.070 |
Why?
| | Immune System | 1 | 2010 | 180 | 0.070 |
Why?
| | Rabbits | 1 | 2010 | 653 | 0.070 |
Why?
| | Propofol | 1 | 2009 | 85 | 0.070 |
Why?
| | Radiography | 1 | 2011 | 853 | 0.070 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2008 | 49 | 0.070 |
Why?
| | Prognosis | 1 | 2017 | 4329 | 0.070 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2008 | 30 | 0.070 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 41 | 0.070 |
Why?
| | Coronary Artery Bypass | 1 | 2010 | 268 | 0.070 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 80 | 0.070 |
Why?
| | Vasodilation | 1 | 2011 | 521 | 0.070 |
Why?
| | Colorado | 1 | 2018 | 4556 | 0.070 |
Why?
| | Phenols | 1 | 2008 | 106 | 0.070 |
Why?
| | Embryonic Stem Cells | 1 | 2008 | 124 | 0.070 |
Why?
| | Ventricular Function | 1 | 2007 | 53 | 0.070 |
Why?
| | Pluripotent Stem Cells | 1 | 2008 | 81 | 0.070 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 153 | 0.070 |
Why?
| | Education | 2 | 2018 | 105 | 0.060 |
Why?
| | Pyruvates | 1 | 2007 | 23 | 0.060 |
Why?
| | Steroids | 1 | 2008 | 160 | 0.060 |
Why?
| | Hypnotics and Sedatives | 1 | 2009 | 222 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2009 | 252 | 0.060 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 874 | 0.060 |
Why?
| | Nurses | 1 | 2009 | 171 | 0.060 |
Why?
| | Dihydrotestosterone | 1 | 2007 | 40 | 0.060 |
Why?
| | Antifungal Agents | 1 | 2008 | 152 | 0.060 |
Why?
| | Positive-Pressure Respiration | 1 | 2008 | 115 | 0.060 |
Why?
| | Fibrosis | 2 | 2020 | 561 | 0.060 |
Why?
| | Deferoxamine | 1 | 2007 | 27 | 0.060 |
Why?
| | Iron Chelating Agents | 1 | 2007 | 17 | 0.060 |
Why?
| | Carbon Dioxide | 1 | 2008 | 227 | 0.060 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2007 | 55 | 0.060 |
Why?
| | Bone Marrow Transplantation | 1 | 2008 | 298 | 0.060 |
Why?
| | rho-Associated Kinases | 1 | 2007 | 82 | 0.060 |
Why?
| | Amino Acids, Dicarboxylic | 2 | 2016 | 9 | 0.060 |
Why?
| | Emphysema | 1 | 2007 | 100 | 0.060 |
Why?
| | Homeostasis | 1 | 2010 | 644 | 0.060 |
Why?
| | Gastrointestinal Diseases | 1 | 2008 | 222 | 0.060 |
Why?
| | Internship and Residency | 1 | 2017 | 1269 | 0.060 |
Why?
| | Epithelial Cells | 2 | 2016 | 1134 | 0.060 |
Why?
| | Interleukin-6 | 2 | 2008 | 779 | 0.060 |
Why?
| | Anesthesia | 1 | 2009 | 257 | 0.060 |
Why?
| | RNA Editing | 1 | 2025 | 26 | 0.060 |
Why?
| | Androgens | 1 | 2007 | 181 | 0.060 |
Why?
| | Research Design | 2 | 2025 | 1139 | 0.060 |
Why?
| | Gene Expression | 2 | 2021 | 1478 | 0.060 |
Why?
| | Endothelin-1 | 1 | 2007 | 181 | 0.060 |
Why?
| | Coronary Disease | 1 | 2008 | 382 | 0.060 |
Why?
| | Inflammation Mediators | 1 | 2008 | 507 | 0.060 |
Why?
| | Beta vulgaris | 1 | 2025 | 14 | 0.060 |
Why?
| | Hospitalization | 1 | 2016 | 2460 | 0.060 |
Why?
| | Cyclic GMP | 1 | 2025 | 90 | 0.060 |
Why?
| | Body Mass Index | 1 | 2014 | 2447 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 821 | 0.050 |
Why?
| | Prospective Studies | 1 | 2017 | 8075 | 0.050 |
Why?
| | MAP Kinase Signaling System | 1 | 2007 | 308 | 0.050 |
Why?
| | Pyrazoles | 1 | 2008 | 517 | 0.050 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2007 | 450 | 0.050 |
Why?
| | NF-kappa B | 1 | 2008 | 667 | 0.050 |
Why?
| | Embolectomy | 1 | 2023 | 13 | 0.050 |
Why?
| | Anti-Inflammatory Agents | 1 | 2007 | 478 | 0.050 |
Why?
| | Orchiectomy | 3 | 2008 | 72 | 0.050 |
Why?
| | Genetic Variation | 2 | 2018 | 976 | 0.050 |
Why?
| | HMGB Proteins | 1 | 2023 | 15 | 0.050 |
Why?
| | Regional Blood Flow | 1 | 2025 | 514 | 0.050 |
Why?
| | Thrombolytic Therapy | 1 | 2023 | 164 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 82 | 0.050 |
Why?
| | Thorax | 1 | 2022 | 51 | 0.050 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2007 | 420 | 0.040 |
Why?
| | Mechanotransduction, Cellular | 1 | 2023 | 121 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2017 | 6464 | 0.040 |
Why?
| | Breath Tests | 1 | 2021 | 77 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2021 | 162 | 0.040 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 675 | 0.040 |
Why?
| | Fibrillar Collagens | 1 | 2020 | 14 | 0.040 |
Why?
| | Kallikreins | 1 | 2020 | 26 | 0.040 |
Why?
| | Aging | 2 | 2008 | 1973 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2022 | 450 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2020 | 54 | 0.040 |
Why?
| | Cattle | 1 | 2023 | 946 | 0.040 |
Why?
| | Incidental Findings | 1 | 2021 | 81 | 0.040 |
Why?
| | Vital Capacity | 1 | 2021 | 292 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2015 | 762 | 0.040 |
Why?
| | Down-Regulation | 2 | 2016 | 618 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2025 | 2191 | 0.040 |
Why?
| | Kinetics | 2 | 2015 | 1568 | 0.040 |
Why?
| | Forced Expiratory Volume | 1 | 2021 | 450 | 0.040 |
Why?
| | Biological Specimen Banks | 1 | 2021 | 118 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 358 | 0.040 |
Why?
| | Mitochondria, Heart | 1 | 2020 | 107 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 668 | 0.040 |
Why?
| | NAD | 1 | 2020 | 79 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2018 | 71 | 0.030 |
Why?
| | Cell Shape | 2 | 2008 | 56 | 0.030 |
Why?
| | Behavior | 1 | 2018 | 90 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2007 | 2601 | 0.030 |
Why?
| | Hepatocyte Growth Factor | 2 | 2008 | 33 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 6032 | 0.030 |
Why?
| | RNA, Small Interfering | 2 | 2011 | 638 | 0.030 |
Why?
| | Critical Care | 1 | 2023 | 702 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 148 | 0.030 |
Why?
| | Curriculum | 1 | 2024 | 1074 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2023 | 924 | 0.030 |
Why?
| | Sleep Apnea Syndromes | 1 | 2018 | 98 | 0.030 |
Why?
| | Job Application | 1 | 2017 | 17 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2018 | 224 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2008 | 174 | 0.030 |
Why?
| | Comprehension | 1 | 2018 | 187 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1247 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2020 | 860 | 0.030 |
Why?
| | Proteomics | 1 | 2023 | 1188 | 0.030 |
Why?
| | Prolyl Hydroxylases | 1 | 2015 | 6 | 0.030 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2008 | 317 | 0.030 |
Why?
| | Gene Silencing | 1 | 2016 | 202 | 0.030 |
Why?
| | Blood Urea Nitrogen | 1 | 2015 | 53 | 0.030 |
Why?
| | Prolyl-Hydroxylase Inhibitors | 1 | 2015 | 6 | 0.030 |
Why?
| | Cyclopentanes | 1 | 2015 | 17 | 0.030 |
Why?
| | Adolescent | 4 | 2021 | 22573 | 0.030 |
Why?
| | Pulmonary Gas Exchange | 1 | 2015 | 116 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2015 | 3551 | 0.030 |
Why?
| | Chloroquine | 1 | 2015 | 54 | 0.030 |
Why?
| | Renal Circulation | 1 | 2015 | 75 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 849 | 0.030 |
Why?
| | Lysosomes | 1 | 2015 | 131 | 0.030 |
Why?
| | Age Factors | 2 | 2015 | 3346 | 0.030 |
Why?
| | Proteolysis | 1 | 2015 | 172 | 0.030 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2015 | 155 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 653 | 0.030 |
Why?
| | Steroid Hydroxylases | 1 | 2014 | 20 | 0.030 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2014 | 17 | 0.030 |
Why?
| | Protein Folding | 1 | 2015 | 277 | 0.030 |
Why?
| | Protein Transport | 1 | 2015 | 442 | 0.030 |
Why?
| | Gene Knock-In Techniques | 1 | 2014 | 61 | 0.030 |
Why?
| | Calcitriol | 1 | 2014 | 58 | 0.020 |
Why?
| | Complement Activation | 1 | 2016 | 399 | 0.020 |
Why?
| | Creatinine | 1 | 2015 | 515 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2014 | 302 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 172 | 0.020 |
Why?
| | Glycolysis | 1 | 2015 | 340 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2015 | 264 | 0.020 |
Why?
| | Mortality | 1 | 2016 | 380 | 0.020 |
Why?
| | Phosphorylation | 2 | 2008 | 1708 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 302 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2015 | 588 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 1430 | 0.020 |
Why?
| | Pyrimidines | 1 | 2015 | 530 | 0.020 |
Why?
| | Computer Simulation | 1 | 2016 | 1003 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 2181 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 920 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 2 | 2008 | 981 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2933 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2399 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 3170 | 0.020 |
Why?
| | Biosensing Techniques | 1 | 2011 | 142 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2123 | 0.020 |
Why?
| | Infant | 2 | 2017 | 10090 | 0.020 |
Why?
| | Mutation | 1 | 2020 | 4090 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1454 | 0.020 |
Why?
| | Propanolamines | 1 | 2009 | 40 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 3210 | 0.020 |
Why?
| | Short Bowel Syndrome | 1 | 2008 | 27 | 0.020 |
Why?
| | Child, Preschool | 2 | 2017 | 11868 | 0.020 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2008 | 41 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2011 | 731 | 0.020 |
Why?
| | Endotoxins | 1 | 2009 | 217 | 0.020 |
Why?
| | Organ Specificity | 1 | 2008 | 309 | 0.020 |
Why?
| | Stromal Cells | 1 | 2008 | 121 | 0.020 |
Why?
| | Tissue and Organ Harvesting | 1 | 2008 | 78 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2009 | 193 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2008 | 94 | 0.020 |
Why?
| | Osteoblasts | 1 | 2008 | 145 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2007 | 112 | 0.020 |
Why?
| | Organ Culture Techniques | 1 | 2007 | 154 | 0.020 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2007 | 24 | 0.020 |
Why?
| | RNA Interference | 1 | 2008 | 475 | 0.020 |
Why?
| | Cell Lineage | 1 | 2008 | 378 | 0.020 |
Why?
| | Tibia | 1 | 2008 | 176 | 0.020 |
Why?
| | Adipocytes | 1 | 2008 | 223 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2008 | 1049 | 0.010 |
Why?
| | Transfection | 1 | 2008 | 927 | 0.010 |
Why?
| | Administration, Oral | 1 | 2009 | 867 | 0.010 |
Why?
| | Femur | 1 | 2008 | 254 | 0.010 |
Why?
| | Diet | 1 | 2014 | 1278 | 0.010 |
Why?
| | Thoracic Surgery | 1 | 2007 | 143 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2009 | 1115 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2008 | 1300 | 0.010 |
Why?
| | Blotting, Western | 1 | 2007 | 1184 | 0.010 |
Why?
| | Tissue Engineering | 1 | 2008 | 438 | 0.010 |
Why?
| | Heart Diseases | 1 | 2007 | 341 | 0.010 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2008 | 364 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2770 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2011 | 2514 | 0.010 |
Why?
| | Child | 2 | 2017 | 22739 | 0.010 |
Why?
| | Glucose | 1 | 2009 | 1048 | 0.010 |
Why?
| | Interleukin-1 | 1 | 2007 | 961 | 0.010 |
Why?
| | Fibroblasts | 1 | 2008 | 1027 | 0.010 |
Why?
| | Fetus | 1 | 2007 | 804 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2823 | 0.010 |
Why?
| | Pregnancy | 1 | 2014 | 7215 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2008 | 2050 | 0.010 |
Why?
| | Neurons | 1 | 2008 | 1652 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 7133 | 0.010 |
Why?
|
|
Lahm's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|